These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24127258)

  • 21. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.
    Scheel TK; Gottwein JM; Mikkelsen LS; Jensen TB; Bukh J
    Gastroenterology; 2011 Mar; 140(3):1032-42. PubMed ID: 21111742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of fluorobenzimidazole HCV NS5A inhibitors.
    Randolph JT; Flentge CA; Donner P; Rockway TW; Patel SV; Nelson L; Hutchinson DK; Mondal R; Mistry N; Reisch T; Dekhtyar T; Krishnan P; Pilot-Matias T; Stolarik DF; Beno DWA; Wagner R; Maring C; Kati WM
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5462-5467. PubMed ID: 27780635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
    Liverton NJ; Carroll SS; Dimuzio J; Fandozzi C; Graham DJ; Hazuda D; Holloway MK; Ludmerer SW; McCauley JA; McIntyre CJ; Olsen DB; Rudd MT; Stahlhut M; Vacca JP
    Antimicrob Agents Chemother; 2010 Jan; 54(1):305-11. PubMed ID: 19841155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
    Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.
    Belema M; Nguyen VN; St Laurent DR; Lopez OD; Qiu Y; Good AC; Nower PT; Valera L; O'Boyle DR; Sun JH; Liu M; Fridell RA; Lemm JA; Gao M; Knipe JO; Meanwell NA; Snyder LB
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4428-35. PubMed ID: 23803586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.
    Yu W; Hu B; Zhong B; Hao J; Lei Z; Agrawal S; Rokosz L; Liu R; Chen S; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2019 Mar; 29(5):700-706. PubMed ID: 30711390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025).
    Ivachtchenko AV; Mitkin OD; Yamanushkin PM; Kuznetsova IV; Bulanova EA; Shevkun NA; Koryakova AG; Karapetian RN; Bichko VV; Trifelenkov AS; Kravchenko DV; Vostokova NV; Veselov MS; Chufarova NV; Ivanenkov YA
    J Med Chem; 2014 Sep; 57(18):7716-30. PubMed ID: 25148100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finger loop inhibitors of the HCV NS5b polymerase. Part II. Optimization of tetracyclic indole-based macrocycle leading to the discovery of TMC647055.
    Vendeville S; Lin TI; Hu L; Tahri A; McGowan D; Cummings MD; Amssoms K; Canard M; Last S; Van den Steen I; Devogelaere B; Rouan MC; Vijgen L; Berke JM; Dehertogh P; Fransen E; Cleiren E; van der Helm L; Fanning G; Van Emelen K; Nyanguile O; Simmen K; Raboisson P
    Bioorg Med Chem Lett; 2012 Jul; 22(13):4437-43. PubMed ID: 22633687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of functionalized bisimidazoles bearing cyclic aliphatic-phenyl motifs as HCV NS5A inhibitors.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5731-5737. PubMed ID: 25453810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of hepatitis C virus NS5A inhibitors.
    Lemm JA; O'Boyle D; Liu M; Nower PT; Colonno R; Deshpande MS; Snyder LB; Martin SW; St Laurent DR; Serrano-Wu MH; Romine JL; Meanwell NA; Gao M
    J Virol; 2010 Jan; 84(1):482-91. PubMed ID: 19812153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.
    Tong L; Yu W; Coburn CA; Meinke PT; Nair AG; Dwyer MP; Chen L; Selyutin O; Rosenblum SB; Jiang Y; Fells J; Hu B; Zhong B; Soll RM; Liu R; Agrawal S; Xia E; Zhai Y; Kong R; Ingravallo P; Nomeir A; Asante-Appiah E; Kozlowski JA
    Bioorg Med Chem Lett; 2016 Oct; 26(20):5132-5137. PubMed ID: 27634194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.
    Gottwein JM; Pham LV; Mikkelsen LS; Ghanem L; Ramirez S; Scheel TKH; Carlsen THR; Bukh J
    Gastroenterology; 2018 Apr; 154(5):1435-1448. PubMed ID: 29274866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.
    Yu W; Tong L; Selyutin O; Chen L; Hu B; Zhong B; Hao J; Ji T; Zan S; Yin J; Ruck RT; Curry S; McMonagle P; Agrawal S; Rokosz L; Carr D; Ingravallo P; Bystol K; Lahser F; Liu R; Chen S; Feng KI; Cartwright M; Asante-Appiah E; Kozlowski JA
    J Med Chem; 2018 May; 61(9):3984-4003. PubMed ID: 29681153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and evaluation of novel tetracyclic benzofurans as palm site allosteric inhibitors of HCV NS5B polymerase.
    Liu H; Dai X; He S; Brockunier L; Marcantonio K; Ludmerer SW; Li F; Feng KI; Nargund RP; Palani A
    Bioorg Med Chem Lett; 2019 Dec; 29(24):126104. PubMed ID: 30389294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor.
    Zhong M; Peng E; Huang N; Huang Q; Huq A; Lau M; Colonno R; Li L
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4508-4512. PubMed ID: 27506559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral activity and resistance of HCV NS5A replication complex inhibitors.
    Gao M
    Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect.
    Belema M; Meanwell NA
    J Med Chem; 2014 Jun; 57(12):5057-71. PubMed ID: 24749835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.